Weight-loss jabs may have wider health benefits, study suggests

The research found that participants who used the class of drugs which includes Wegovy and Ozempic had a lower risk of 42 health conditions

Semaglutide (GLP-1) weight-loss drug Wegovy, made by pharmaceutical company Novo Nordisk, which are designed to treat type 2 diabetes, but are widely known for their effect on weight loss. Picture: James Manning/PA

The use of weight-loss jabs may be associated with wider health benefits including lower risk of stroke and dementia, a study has suggested.

The research, published in the scientific journal Nature Medicine, found that participants who used the class of drugs which includes Wegovy and Ozempic had a lower risk of 42 health conditions compared with those who took other diabetes medications.